Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01499303 · ClinicalTrials.gov registry record · Phase 2
Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer
A Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 101
- Enrollment target
- 20
- Study locations
NCT01499303: Completed Phase 2 study of Diffuse Large B Cell Lymphoma, sponsored by AstraZeneca.
NCT01499303 is a Phase 2 study of Diffuse Large B Cell Lymphoma that has completed, run by AstraZeneca. The registered enrollment target is 101 participants, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01499303, a Phase 2 study of Diffuse Large B Cell Lymphoma, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 101 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)
Primary Outcome
Patients were assessed using the revised response criteria for malignant lymphoma (Cheson). Patients were assessed for response, with CT and FDG-PET scans at 8 weeks, then every 12 weeks until radiological progression by clinical CT. Complete response (CR) was defined as disappearance of all target and non-target lesions in the liver and spleen and all lymph node masses regressed to normal size. Partial response (PR) was defined as ≥50% reduction in sum of the product of the diameters (SPD) for
Conditions Studied
Interventions
- DRUG Fostamatinib
Study Locations (20)
New York
- Research Site - New York
- Research Site - Rochester
Texas
- Research Site - Houston
- Research Site - San Antonio
Alabama
- Research Site - Huntsville
Colorado
- Research Site - Denver
Connecticut
- Research Site - New Haven
Florida
- Research Site - Sarasota
Georgia
- Research Site - Atlanta
Iowa
- Research Site - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
What the finished NCT01499303 record still lists
NCT01499303 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (54% lower).
The record links to 1 condition, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Fostamatinib is the first listed.
NCT01499303 names 20 study sites across 18 states, led by New York, Texas, Alabama.
Frequently Asked Questions
What is clinical trial NCT01499303 about?
NCT01499303 is a clinical study titled "Study to Learn if 200mg Test Drug (Fostamatinib) Helps People With Large B-Cell Lymphoma,a Type of Blood Cancer". This study will evaluate the effectiveness of fostamatinib (200 mg twice a day) in patients with worsening or unmanageable lymphoma with a specific type of lymphoma called Diffuse Large B-Cell Lymphoma (abbreviated as DLBCL)
What is the current status of trial NCT01499303?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2011-12. Estimated completion is 2013-10.
What conditions does trial NCT01499303 study?
This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma.
What interventions are being tested in trial NCT01499303?
The interventions under investigation include: Fostamatinib (DRUG).
Who is sponsoring clinical trial NCT01499303?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01499303 being conducted?
This trial has 20 study locations across Alabama, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diffuse Large B Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01499303's enrollment target sits among peer trials
101 41st of 114 higher than 74 of 114 other Diffuse Large B Cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diffuse Large B Cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma
RECRUITING · Phase 2
-
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
RECRUITING · Phase 2
-
Emapalumab Prevention of CAR-T Cell Associated Toxicities
RECRUITING · Phase 2
-
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RECRUITING · Phase 2
-
Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy
RECRUITING · Phase 2
-
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04033497 · 101 participants · NA
Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases
- NCT05111574 · 101 participants · Phase 2
Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
- NCT05984680 · 101 participants
COPD Care Pathway Among Patients With Cancer
- NCT06266299 · 101 participants · Phase 1
A Study of KK2269 in Adult Participants With Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia